{
  "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
  "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
  "summary": [
    {
      "type": "bullet",
      "text": "Patient-reported outcomes (PROs) are increasingly recognized as crucial endpoints in evaluating treatments for transthyretin amyloid cardiomyopathy (ATTR-CM), contributing to regulatory approvals both in pivotal studies and broader heart failure trials."
    },
    {
      "type": "bullet",
      "text": "A study comparing the Kansas City Cardiomyopathy Questionnaire (KCCQ), Minnesota Living with Heart Failure Questionnaire (MLHFQ), and Euro-Qol 5 dimension-5 levels (EQ-5D-5 L) found that EQ-5D-5 L and MLHFQ were predictors of all-cause mortality in ATTR-CM, emphasizing the importance of PROs in understanding patient experience."
    },
    {
      "type": "bullet",
      "text": "Recent FDA-approved therapies have been approved based on improvements in PROs and HR-QoL, highlighting a shift towards recognizing symptom improvement and functional status as clinically significant."
    }
  ],
  "model": "granite4:tiny-h"
}